Table of Contents
ISRN Pharmacology
Volume 2013, Article ID 146579, 7 pages
http://dx.doi.org/10.1155/2013/146579
Research Article

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

1Departments of Pharmacy and Clinical Pharmacy, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
2Departments of Medicine and Endocrinology, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
3Department of Medical Statistics and Epidemiology, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
4Departments of Public Health and Medical Education, Weill Cornell Medical College in Qatar, P.O. Box 3050, Doha, Qatar
5Department of Evidence for Population Health Unit, School of Epidemiology and Health Sciences, The University of Manchester, Manchester, UK
6Pediatric Intensive Care Unit, Department of Pediatrics, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar

Received 6 December 2012; Accepted 3 January 2013

Academic Editors: T. Kumai and T. B. Vree

Copyright © 2013 Lolwa Barakat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), “Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report,” Circulation, vol. 106, no. 25, article 3143, 2002. View at Google Scholar
  2. A. Bener, M. Zirie, I. M. Janahi, A. O. A. A. Al-Hamaq, M. Musallam, and N. J. Wareham, “Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar,” Diabetes Research and Clinical Practice, vol. 84, no. 1, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Bener, M. Zirie, M. Musallam, Y. S. Khader, and A. O. A. A. Al-Hamaq, “Prevalence of metabolic syndrome according to adult treatment panel III and international diabetes federation criteria: a population-based study,” Metabolic Syndrome and Related Disorders, vol. 7, no. 3, pp. 221–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bener, E. Dafeeah, S. Ghuloum, and A. O. A. A. Al-Hamaq, “Association between psychological distress and gastrointestinal symptoms in type 2 diabetes mellitus,” World Journal of Diabetes, vol. 3, no. 6, pp. 123–129, 2012. View at Publisher · View at Google Scholar
  5. J. D. Brunzell, M. Davidson, C. D. Furberg et al., “Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the american college of cardiology foundation,” Diabetes Care, vol. 31, no. 4, pp. 811–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. T. O'Brien, T. T. Nguyen, and B. R. Zimmerman, “Hyperlipidemia and diabetes mellitus,” Mayo Clinic Proceedings, vol. 73, no. 10, pp. 969–976, 1998. View at Google Scholar · View at Scopus
  7. R. M. Krauss, “Lipids and lipoproteins in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 6, pp. 1496–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. M. Colhoun, D. J. Betteridge, P. N. Durrington et al., “Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial,” The Lancet, vol. 364, no. 9435, pp. 685–696, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Shepherd, P. Barter, R. Carmena et al., “Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating To new targets (TNT) study,” Diabetes Care, vol. 29, no. 6, pp. 1220–1226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. American Diabetes Association, “Standards of medical care in diabetes,” Diabetes Care, vol. 32, supplement 1, pp. S13–S61, 2009. View at Google Scholar
  11. S. J. Nicholls, E. M. Tuzcu, I. Sipahi et al., “Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis,” The Journal of the American Medical Association, vol. 297, no. 5, pp. 499–508, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. R. Henry, “Preventing cardiovascular complications of type 2 diabetes: focus on lipid management,” Clinical Diabetes, vol. 19, no. 3, pp. 113–120, 2001. View at Publisher · View at Google Scholar
  13. D. J. Maron, S. Fazio, and M. F. Linton, “Current perspectives on statins,” Circulation, vol. 101, no. 2, pp. 207–213, 2000. View at Google Scholar · View at Scopus
  14. R. S. Rosenson, “Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia,” Expert Review of Cardiovascular Therapy, vol. 1, no. 4, pp. 495–505, 2003. View at Google Scholar · View at Scopus
  15. P. H. Jones, M. H. Davidson, E. A. Stein et al., “Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial),” American Journal of Cardiology, vol. 92, no. 2, pp. 152–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. S. Brown, R. G. Bakker-Arkema, L. Yellen et al., “Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin,” Journal of the American College of Cardiology, vol. 32, no. 3, pp. 665–672, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. B. A. Hamelin and J. Turgeon, “Hydrophilicity/Lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors,” Trends in Pharmacological Sciences, vol. 19, no. 1, pp. 26–37, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. A. R. Vasudevan, Y. S. Hamirani, and P. H. Jones, “Safety of statins: effects on muscle and the liver,” Cleveland Clinic Journal of Medicine, vol. 72, no. 11, pp. 990–1001, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. A. Alsheikh-Ali and R. H. Karas, “The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials,” Current Atherosclerosis Reports, vol. 11, no. 2, pp. 100–104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Kashani, C. O. Phillips, J. M. Foody et al., “Risks associated with statin therapy: a systematic overview of randomized clinical trials,” Circulation, vol. 114, no. 25, pp. 2788–2797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Armitage, “The safety of statins in clinical practice,” The Lancet, vol. 370, no. 9601, pp. 1781–1790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Evans and A. Rees, “Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?” Drug Safety, vol. 25, no. 9, pp. 649–663, 2002. View at Google Scholar · View at Scopus
  23. Annual Health Report, Vital Health Statistics, Hamad Medical Corporation, Doha, Qatar, 2010.
  24. World Health Organization, “Definition, diagnosis and classification of diabetes mellitus and its complications,” Report of a WHO Consultation WHOINCDINCS/99. 2, World Health Organization, Geneva, Switzerland, 1999. View at Google Scholar
  25. J. M. Mckenney, “Efficacy and safety of rosuvastatin in treatment of dyslipidemia,” American Journal of Health-System Pharmacy, vol. 62, no. 10, pp. 1033–1047, 2005. View at Google Scholar · View at Scopus
  26. M. B. Clearfield, J. Amerena, J. P. Bassand et al., “Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia—prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR),” Trials, vol. 7, article 35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. B. G. Brown, X. Q. Zhao, and M. C. Cheung, “Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence,” Journal of Clinical Lipidology, vol. 1, no. 1, pp. 88–94, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Tiwari, V. Bansal, A. Chugh, and K. Mookhtiar, “Statins and myotoxicity: a therapeutic limitation,” Expert Opinion on Drug Safety, vol. 5, no. 5, pp. 651–666, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Björnsson, E. I. Jacobsen, and E. Kalaitzakis, “Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing,” Journal of Hepatology, vol. 56, no. 2, pp. 374–380, 2012. View at Publisher · View at Google Scholar
  30. K. Douglas, P. G. O'Malley, and J. L. Jackson, “Meta-analysis: the effect of statins on albuminuria,” Annals of Internal Medicine, vol. 145, no. 2, pp. 117–124, 2006. View at Google Scholar · View at Scopus
  31. J. Atthobari, A. H. Brantsma, R. T. Gansevoort et al., “The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study,” Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3106–3114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. McKenney, “Defining the pharmacological profile of rosuvastatin: a look at statin therapy for dyslipidemia,” France foundation web site poster: advances in managing hyperlipidemia online continuing medical education activity, 2005, http://www.francefoundation.com/cme/posttest/pages/amh_posters.pdf.